CytomX Therapeutics - CTMX Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1 year price targets for CytomX Therapeutics' stock. Their CTMX share price forecasts range from $1.50 to $11.00. On average, they expect the company's share price to reach $4.89 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.

CytomX Therapeutics' stock was trading at $4.33 at the beginning of 2022. Since then, CTMX shares have decreased by 67.0% and is now trading at $1.43.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CTMX earnings forecast.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biotechnology company had revenue of $18.17 million for the quarter, compared to the consensus estimate of $18.43 million. CytomX Therapeutics had a negative net margin of 133.42% and a negative trailing twelve-month return on equity of 121.88%.

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (4.17%), Renaissance Technologies LLC (2.21%), Millennium Management LLC (2.19%), Laurion Capital Management LP (1.93%), Platinum Investment Management Ltd. (1.86%) and Pictet Asset Management SA (1.00%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $1.43.

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $94.31 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

The company employs 174 workers across the globe.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.